Insilico enters $100 million AI deal with Lilly

Cambridge, USA-based AI-driven biotech Insilico Medicine has announced a research collaboration with Eli Lilly (NYSE: LLY), under which they will combine Insilico's state-of-the-art pharma artificial intelligence (AI) platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.

Insilico will utilize its validated Pharma.AI platform and deep drug discovery expertise to generate, design, and optimize candidate compounds against targets defined under the agreement. Insilico is eligible to receive over $100 million including an upfront, milestone payments, and tiered royalties on net sales upon commercialization of any resulting drug products.

"We are delighted to collaborate with Lilly, a global leader in the pharmaceutical industry, renowned for its commitment to medical innovation," said Alex Zhavoronkov, founder and co-chief executive of Insilico Medicine.  "Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognizes Insilico's AI-driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide," he added.